Nonsense-mediated decay: linking a basic cellular process to human disease

References

• Culbertson MR. RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet.15(2), 74–80 (1999).
   PubMed Web of Science ®Google Scholar
• Carter MS, Li S, Wilkinson MF. A splicing-dependent regulatory mechanism that detects translation signals. EMBO J.15(21), 5965–5975 (1996).
   PubMedGoogle Scholar
• Maquat LE, Li X. Mammalian heat shock p70 and histone H4 transcripts, which derive from naturally intronless genes, are immune to nonsense-mediated decay. RNA7(3), 445–456 (2001).
   PubMedGoogle Scholar
• Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits multiple proteins 20–24 nucleotides upstream of mRNA exon–exon junctions. EMBO J.19(24), 6860–6869 (2000).
   PubMed Web of Science ®Google Scholar
• Buhler M, Steiner S, Mohn F, Paillusson A, Mühlemann O. EJC-independent degradation of nonsense immunoglobulin-µ mRNA depends on 3´ UTR length. Nat. Struct. Mol. Biol.13(5), 462–464 (2006).
   PubMed Web of Science ®Google Scholar
• Rajavel KS, Neufeld EF. Nonsense-mediated decay of human HEXA mRNA. Mol. Cell Biol.21(16), 5512–5519 (2001).
   PubMedGoogle Scholar
• LeBlanc JJ, Beemon KL. Unspliced Rous sarcoma virus genomic RNAs are translated and subjected to nonsense-mediated mRNA decay before packaging. J. Virol.78(10), 5139–5146 (2004).
   PubMedGoogle Scholar
• Singh G, Rebbapragada I, Lykke-Andersen J. A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay. PLoS Biol.6(4), e111 (2008).
   PubMed Web of Science ®Google Scholar
• Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat. Struct. Mol. Biol.16(2), 107–113 (2009).
   PubMed Web of Science ®Google Scholar
• Shibuya T, Tange TØ, Sonenberg N, Moore MJ. eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nat. Struct. Mol. Biol.11(4), 346–351 (2004).
   PubMed Web of Science ®Google Scholar
• Tange TO, Nott A, Moore MJ. The ever-increasing complexities of the exon junction complex. Curr. Opin. Cell Biol.16(3), 279–284 (2004).
   PubMed Web of Science ®Google Scholar
• Weng Y, Czaplinski K, Peltz SW. Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein. Mol. Cell Biol.16(10), 5477–5490 (1996).
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Czaplinski K, Trifillis P, He F, Jacobson A, Peltz SW. Characterization of the biochemical properties of the human UPF1 gene product that is involved in nonsense-mediated mRNA decay. RNA6(9), 1226–1235 (2000).
   PubMedGoogle Scholar
• Kim YK, Furic L, Desgroseillers L, Maquat LE. Mammalian Staufen1 recruits Upf1 to specific mRNA 3´UTRs so as to elicit mRNA decay. Cell120(2), 195–208 (2005).
   PubMed Web of Science ®Google Scholar
• Kaygun H, Marzluff WF. Regulated degradation of replication-dependent histone mRNAs requires both ATR and Upf1. Nat. Struct. Mol. Biol.12(9), 794–800 (2005).
   PubMed Web of Science ®Google Scholar
• Medghalchi SM, Frischmeyer PA, Mendell JT, Kelly AG, Lawler AM, Dietz HC. Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum. Mol. Genet.10(2), 99–105 (2001).
   PubMedGoogle Scholar
• Azzalin CM, Lingner J. The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. Curr. Biol.16(4), 433–439 (2006).
   PubMedGoogle Scholar
• Serin G, Gersappe A, Black JD, Aronoff R, Maquat LE. Identification and characterization of human orthologues to Saccharomyces cerevisiae Upf2 protein and Upf3 protein (Caenorhabditis elegans SMG-4). Mol. Cell Biol.21(1), 209–223 (2001).
   PubMedGoogle Scholar
• Kadlec J, Guilligay D, Ravelli RB, Cusack S. Crystal structure of the UPF2-interacting domain of nonsense-mediated mRNA decay factor UPF1. RNA12(10), 1817–1824 (2006).
   PubMedGoogle Scholar
• Kadlec J, Izaurralde E, Cusack S. The structural basis for the interaction between nonsense-mediated mRNA decay factors UPF2 and UPF3. Nat. Struct. Mol. Biol.11(4), 330–337 (2004).
   PubMed Web of Science ®Google Scholar
• Gehring NH, Kunz JB, Neu-Yilik G et al. Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Mol. Cell20(1), 65–75 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkinson MF. The cycle of nonsense. Mol. Cell12(5), 1059–1061 (2003).
   PubMedGoogle Scholar
• Brumbaugh KM, Otterness DM, Geisen C et al. The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol. Cell14(5), 585–598 (2004).
   PubMed Web of Science ®Google Scholar
• Chawla R, Azzalin CM. The telomeric transcriptome and SMG proteins at the crossroads. Cytogenet. Genome Res.122(3–4), 194–201 (2008).
   PubMed Web of Science ®Google Scholar
• Anders KR, Grimson A, Anderson P. SMG-5, required for C. elegans nonsense-mediated mRNA decay, associates with SMG-2 and protein phosphatase 2A. EMBO J.22(3), 641–650 (2003).
   PubMedGoogle Scholar
• Unterholzner L, Izaurralde E. SMG7 acts as a molecular link between mRNA surveillance and mRNA decay. Mol. Cell16(4), 587–596 (2004).
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Kashima I, Fauser M, Saulière J, Izaurralde E. SMG6 is the catalytic endonuclease that cleaves mRNAs containing nonsense codons in metazoan. RNA14(12), 2609–2617 (2008).
   PubMed Web of Science ®Google Scholar
• Cho H, Kim KM, Kim YK. Human proline-rich nuclear receptor coregulatory protein 2 mediates an interaction between mRNA surveillance machinery and decapping complex. Mol. Cell33(1), 75–86 (2009).
   PubMedGoogle Scholar
• Hall GW, Thein S. Nonsense codon mutations in the terminal exon of the β-globin gene are not associated with a reduction in β-mRNA accumulation: a mechanism for the phenotype of dominant β-thalassemia. Blood83(8), 2031–2037 (1994).
   PubMed Web of Science ®Google Scholar
• Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum. Mutat.19(4), 423–434 (2002).
   PubMed Web of Science ®Google Scholar
• Anczukow O, Ware MD, Buisson M et al. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum. Mutat.29(1), 65–73 (2008).
   PubMedGoogle Scholar
• Dietz HC, McIntosh I, Sakai LY et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics17(2), 468–475 (1993).
   PubMed Web of Science ®Google Scholar
• Bashyam MD. Studies on nonsense mediated decay reveal novel therapeutic options for genetic diseases. Recent Pat. DNA Gene Seq.3(1), 7–15 (2009).
   PubMedGoogle Scholar
• Kerr TP, Sewry CA, Robb SA, Roberts RG. Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay? Hum. Genet.109(4), 402–407 (2001).
   PubMedGoogle Scholar
• Aartsma-Rus A, De Winter CL, Janson AA et al. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol. Ther.14(3), 401–407 (2006).
   PubMed Web of Science ®Google Scholar
• Sheppard DN, Ostedgaard LS, Rich DP, Welsh MJ. The amino-terminal portion of CFTR forms a regulated Cl- channel. Cell76(6), 1091–1098 (1994).
   PubMed Web of Science ®Google Scholar
• Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med.10(6), 547–552 (2004).
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Yahav Y, Yaacov Y et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med.349(15), 1433–1441 (2003).
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet372(9640), 719–727 (2008).
   PubMed Web of Science ®Google Scholar
• Sako Y, Usuki F, Suga H. A novel therapeutic approach for genetic diseases by introduction of suppressor tRNA. Nucleic Acids Symp. Ser. (Oxf.)50, 239–240 (2006).
   Google Scholar